Soligenix, Inc. (NASDAQ: SNGX) announced that results from its Phase 2a study of SGX945 for treating Behçet's Disease have been ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE